Background and Objectives: The genetic background of the DVa category phenotype has been described in two Caucasian individuals. We were interested in the RHD sequence of 7 Japanese DVa individuals and their families. Materials and Methods: With SSP–PCR we tested exons 4, 5 and 7 of the RHD gene and used restriction enzymes for testing nucelotide associated with the DVa phenotype. Results: A single RHD G667 C697 allele was present in 5 individuals with DVa category phenotype, and in 2 individuals we found a D–CE–D hybrid gene (exon 5 had been replaced). The DVaCe gene complex was found in all families. Conclusion: The changes of the RHD gene described in European DVa individuals were also observed in Japanese families.

1.
Tippett P, Lomas FC, Wallace M: The Rh antigen D: partial D antigens and associated low incidence antigens. Vox Sang 1996;70:123– 131.
2.
Rouillac C, Colin Y, Hughes JN, Beolet M, D’Ambrosio AM, Cartron JP, Le Van Kim C: Transcript analysis of D category phenotypes predicts hybrid Rh D–CE–D proteins associated with alteration of D epitopes. Blood 1995; 85:2937–2944.
3.
Legler TJ, Maas JH, Blaschke V, Malekan M, Ohto H, Lynen R, Bustami N, Schwartz DWM, Mayr WR, Köhler M, Panzer S: RHD genotyping in weak D phenotypes by multiple polymerase chain reactions. Transfusion 1998;38: 434–440.
4.
Aubin JT, Le Van Kim C, Mouro I, Colin Y, Bignozzi C, Brossard Y, Cartron JP: Specificity and sensitivity of RHD genotyping methods by PCR–based DNA amplification. Br J Haematol 1997;98:356–364.
5.
Mollison PL, Engelfriet CP, Contreras M: Blood Transfusion in Clinical Medicine, ed 10. Oxford, Blackwell, 1997.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.